Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy

With the success of ipilimumab and promise of programmed death-1 pathway-targeted agents, the field of tumor immunotherapy is expanding rapidly. Newer targets for clinical development include select members of the tumor necrosis factor receptor (TNFR) family. Agonist antibodies to these co-stimulato...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaer, David A, Hirschhorn-Cymerman, Daniel, Wolchok, Jedd D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030310/
https://www.ncbi.nlm.nih.gov/pubmed/24855562
http://dx.doi.org/10.1186/2051-1426-2-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030310/
https://www.ncbi.nlm.nih.gov/pubmed/24855562
http://dx.doi.org/10.1186/2051-1426-2-7

Ejemplares similares